On March 19, 2026, the FDA approved Wegovy HD — a 7.2mg once-weekly semaglutide injection — in just 54 days from filing. To put that speed in context: the standard FDA review timeline is 10 to 12 months. This was the first GLP-1 receptor agonist approved under the Commissioner's National Priority Voucher pilot program, a new expedited pathway reserved for products that address critical national health priorities.
The clinical data behind the fast-track was decisive: 20.7% mean body weight loss. One in three patients on the 7.2mg dose lost 25% or more of their body weight. Those numbers close the gap between semaglutide and tirzepatide — without requiring patients to switch medications.
The STEP UP Trial: What the Data Shows
The 72-week STEP UP trial enrolled 1,407 adults with obesity (BMI of 30 or higher) without diabetes and randomly assigned them to once-weekly subcutaneous semaglutide 7.2mg, 2.4mg, or placebo in a 5:1:1 ratio.
The results at 72 weeks:
- Semaglutide 7.2mg: 20.7% mean weight loss; approximately 1 in 3 patients achieved 25%+ weight loss
- Semaglutide 2.4mg: Approximately 14-15% mean weight loss (consistent with prior STEP trial data)
- Placebo: Minimal weight change
The difference between 7.2mg and 2.4mg — roughly six additional percentage points of weight loss — is clinically meaningful. For a 250-pound person, that's the difference between losing about 37 pounds and losing about 52 pounds. At the higher dose, semaglutide now produces weight loss results that approach tirzepatide (Zepbound) territory, which averaged 20-22% weight loss in the SURMOUNT trials.
Who Qualifies for the Higher Dose
Wegovy HD isn't a starting dose. The FDA approved it specifically for adults who have tolerated the standard 2.4mg dose for at least four weeks and for whom additional weight reduction is clinically indicated. This means:
- You must already be on Wegovy 2.4mg and tolerating it well
- Your clinician determines that you haven't achieved sufficient weight loss at the standard dose
- There's a clinical basis for stepping up rather than switching to a different medication
In practice, this creates a step-up pathway within the semaglutide product line: you start with the standard Wegovy titration (0.25mg → 0.5mg → 1.0mg → 1.7mg → 2.4mg), and if 2.4mg isn't producing adequate results after at least four weeks, your prescriber can move you to 7.2mg.
How It's Delivered
Wegovy HD comes in a single-dose prefilled pen — one injection per week, administered subcutaneously in the abdomen, thigh, or upper arm. This is the same injection technique and schedule as the lower-dose Wegovy pens. Novo Nordisk launched the product in U.S. pharmacies in April 2026, with distribution through major retail pharmacies, telehealth partners, and NovoCare/GoodRx channels.
The 7.2mg dose is already approved in the EU and UK, where it's currently administered as three 2.4mg injections in one sitting. Novo has applied for approval of a single-dose pen in those markets, with regulatory decisions expected in the second half of 2026.
What This Means for Telehealth Patients
For patients using telehealth to manage their GLP-1 treatment, Wegovy HD raises an important question: does your platform support dose escalation and clinical monitoring for higher doses?
The step-up from 2.4mg to 7.2mg isn't a simple refill change — it requires clinical evaluation, patient education about what to expect at the higher dose (including potentially more pronounced side effects during adjustment), and ideally some metabolic monitoring. Platforms with robust follow-up protocols are better positioned to manage this transition safely than platforms with minimal clinical oversight.
The Bigger Picture: Semaglutide's Growing Portfolio
Wegovy HD joins an increasingly comprehensive semaglutide product lineup in the U.S.:
- Wegovy 2.4mg injection: Standard once-weekly injection for obesity and cardiovascular risk reduction
- Oral Wegovy 25mg pill: Once-daily tablet for weight loss (launched alongside HD)
- Wegovy HD 7.2mg injection: Higher-dose step-up for patients needing more weight loss
- Ozempic: Semaglutide for type 2 diabetes (1.0mg and 2.0mg)
- Rybelsus: Oral semaglutide for diabetes
No other GLP-1 drug class has this breadth of formulations. For telehealth providers, this means patients can potentially stay within the semaglutide ecosystem across different delivery methods, doses, and indications — all manageable through a single prescriber relationship.